Ankita Choudhury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ankita Choudhury has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Abu Md Ashif Ikbal
Department of Pharmaceutical Sciences, Assam University (A Central University), Silchar-788011, India
1 shared publication - Ankita Roy
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India
1 shared publication - Bani Kumar Jana
Dibrugarh University
1 shared publication - Bedanta Bhattacharjee
School of Pharmaceutical Sciences, Girijananda Chowdhury University-Tezpur Campus, Tezpur, India
1 shared publication - Bhrigumani Kalita
Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam 786004, India
1 shared publication - Bibek Sinha
Department of Pharmacy, Tripura University, Suryamaninagar, Tripura 799022, India
1 shared publication
Latest Publications
- Open Access
- 27 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 1 (2) , 182-203
Advances of cassava starch-based composites in novel and conventional drug delivery systems: a state-of-the-art review
Starch has emerged as a new attractive biopolymer for use in pharmaceutical applications, owing to its distinctive physical, chemical and functional properties. This biopolymer has several potential advantages: it is biocompatible, low cost, non-toxic and easily isolated from plant sources. In the pharmaceutical field, starch is used as a raw material for developing various drug delivery platforms. Generally, cassava starch (tapioca) is obtained from the swollen roots of the perennial shrub Manihot esculenta and it contains a low amount of amylose in contrast to other varieties of starches. Because of this reason, cassava starch exhibits various prime benefits, including a low gelatinization temperature, higher swelling power and a relatively high viscosity paste, making it a preferable excipient for pharmaceutical applications. However, cassava starches in their native form are not effective for many applications because of their inefficiency in handling various processing requirements like high temperature and diverse pH. Their applicability can be enhanced by starch modification. These functional starches have demonstrated outstanding prospects as primary excipients in many pharmaceutical formulations. In this article, we discuss the potential application of cassava starches in the pharmaceutical and biomedical fields, along with the toxicity assessment of modified cassava starches.
- 27 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 1 (2) , 182-203
Open AccessAdvances of cassava starch-based composites in novel and conventional drug delivery systems: a state-of-the-art review
Starch has emerged as a new attractive biopolymer for use in pharmaceutical applications, owing to its distinctive physical, chemical and functional properties. This biopolymer has several potential advantages: it is biocompatible, low cost, non-toxic and easily isolated from plant sources. In the pharmaceutical field, starch is used as a raw material for developing various drug delivery platforms. Generally, cassava starch (tapioca) is obtained from the swollen roots of the perennial shrub Manihot esculenta and it contains a low amount of amylose in contrast to other varieties of starches. Because of this reason, cassava starch exhibits various prime benefits, including a low gelatinization temperature, higher swelling power and a relatively high viscosity paste, making it a preferable excipient for pharmaceutical applications. However, cassava starches in their native form are not effective for many applications because of their inefficiency in handling various processing requirements like high temperature and diverse pH. Their applicability can be enhanced by starch modification. These functional starches have demonstrated outstanding prospects as primary excipients in many pharmaceutical formulations. In this article, we discuss the potential application of cassava starches in the pharmaceutical and biomedical fields, along with the toxicity assessment of modified cassava starches.
- Open Access
- 30 September 2021
- Published by International Journal of Pharmaceutical Sciences and Drug Research in International Journal of Pharmaceutical Sciences and Drug Research
- p. 589-599
A Comprehensive Review on Brugada Syndrome: Etiology, Hormonal role, Current Treatment Regimen, and Role of Polyunsaturated Fatty Acids
Brugada syndrome is a disorder caused by alteration or mutation in the ion channels, abnormal ECG resulting in elevated ST segment and blockage of right bundle brank. It has a genetic history and can be passed down from the parents to their offspring and may be further complicated if someone already had a cardiac arrest or other cardiac-related issues. At present, there is no permanent cure strategy available to treat this disorder. However, some surgical and pharmacological intervention approaches, such as the use of defibrillators, catheters can provide some relief, but due to their excessive cost and complications, their use has been limited. Polyunsaturated fatty acids (PUFA) components: Eicosapentaenoic acid and docosahexaenoic acid were found to play a significant role in reducing the cardiovascular events and mortality rate. The primary sources of these fatty acids are fish and fish oils. This review attempts to summarize the cardioprotective role of PUFA in preventing ventricular arrhythmias and Brugada syndrome through alteration of cardiac ion channels.
- 30 September 2021
- Published by International Journal of Pharmaceutical Sciences and Drug Research in International Journal of Pharmaceutical Sciences and Drug Research
- p. 589-599
Open AccessA Comprehensive Review on Brugada Syndrome: Etiology, Hormonal role, Current Treatment Regimen, and Role of Polyunsaturated Fatty Acids
Brugada syndrome is a disorder caused by alteration or mutation in the ion channels, abnormal ECG resulting in elevated ST segment and blockage of right bundle brank. It has a genetic history and can be passed down from the parents to their offspring and may be further complicated if someone already had a cardiac arrest or other cardiac-related issues. At present, there is no permanent cure strategy available to treat this disorder. However, some surgical and pharmacological intervention approaches, such as the use of defibrillators, catheters can provide some relief, but due to their excessive cost and complications, their use has been limited. Polyunsaturated fatty acids (PUFA) components: Eicosapentaenoic acid and docosahexaenoic acid were found to play a significant role in reducing the cardiovascular events and mortality rate. The primary sources of these fatty acids are fish and fish oils. This review attempts to summarize the cardioprotective role of PUFA in preventing ventricular arrhythmias and Brugada syndrome through alteration of cardiac ion channels.